Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine

Jonathan Brammer, Zachary Braunstein, Patrick Stevens, Zachary Hutchins, Giulia Calabretto, Soprina Guarneri, Eric McLaughlin, Amy Boles, John Reneau, Walter Hanel, Enrica Marchi, Maciej Pietrzak, Anjali Mishra

Blood (2025) 146 (Supplement 1): 890.

https://doi.org/10.1182/blood-2025-890

Published: 2025

Journal Articles

PRMT5 is a therapeutic vulnerability in cutaneous T-cell lymphoma

Nicole Peterman, Pushpa Lata, Christoph Weigel, Sydney Leon, Ian Hout, Wing Chan, Ronny Schmidt, Ha Tran, Youssef Youssef, Peggy Scherle, Neha Bhagwat, John Reneau, Catherine Chung, Jonathan Brammer, Ryan Wilcox, Lapo Alinari, Robert Baiocchi, Walter Hanel

Blood (2025) 146 (Supplement 1): 1529.

https://doi.org/10.1182/blood-2025-1529

Published: 2025

Journal Articles

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Blood (2025) 146 (Supplement 1): 1054.

https://doi.org/10.1182/blood-2025-1054

Published: 2025

Journal Articles

Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities.

Zachary Hutchins, Robyn Keller, Molly Halloran, Colleen Isabelle, Kathleen McConnell, Amy Boles, Maria Altemus, Rachel Burzinski, Giulia Calabretto, Nitin Chakravarti, Jonathan Brammer, Anjali Mishra

Blood (2025) 146 (Supplement 1): 5035.

https://doi.org/10.1182/blood-2025-5035

Published: 2025

Journal Articles

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Blood (2025) 146 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2025-4523

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Blood (2025) 146 (Supplement 1): 1935.

https://doi.org/10.1182/blood-2025-1935

Published: 2025

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

Jiasheng Wang, Tuan Phan, Pedro Silberman, Evandro Bezerra, Jonathan Brammer, Hannah Choe, Nathan Denlinger, Marcos de Lima, Sam Penza, Gabriela Sanchez-Petitto, Polina Shindiapina, Sumithira Vasu, Sarah Wall, Reza Averly, Xia Ning, Bradley Blaser

Blood (2025) 146 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2025-4352

Published: 2025

Journal Articles

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Timothy Voorhees, Rina Welkie, Hemalatha Rao, Yazeed Sawalha, David Bond, Audrey Sigmund, Yun Choi, John Reneau, Walter Hanel, Polina Shindiapina, Jonathan Brammer, Beth Christian, Lapo Alinari, Nancy Bartlett, Kami Maddocks, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 8240.

https://doi.org/10.1182/blood-2025-8240

Published: 2025

Journal Articles

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Yazeed Sawalha, Marie Hu, Rina Welkie, Aubree Shoemaker, Yun Choi, Audrey Sigmund, Timothy Voorhees, David Bond, John Reneau, Lapo Alinari, Jonathan Brammer, Beth Christian, Robert Baiocchi, Veronika Bachanova, Kami Maddocks

Blood (2025) 146 (Supplement 1): 8239.

https://doi.org/10.1182/blood-2025-8239

Published: 2025

Journal Articles

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Deepa Jagadeesh, Stefan Barta, Seunghee Margevicius, Jonathan Brammer, Jeanette Comstock, Pingfu Fu, Rahul Mishra, Montreh Tavakkoli, Alma Habib, Imran Nizamuddin, Tiffany Chang, Melissa Pulitzer, Cesar Virgen, Sharina Macapagal, Madiha Iqbal, N. Nora Bennani, Frederick Lansigan, Neha Mehta-Shah, Zachary Epstein-Peterson

Blood (2025) 146 (Supplement 1): 5433.

https://doi.org/10.1182/blood-2025-5433

Published: 2025

Journal Articles

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

Pier Luigi Zinzani, Neha Mehta-Shah, Jasmine Zain, Giuseppe Gritti, Lauren Pinter-Brown, Koji Izutsu, Ohad S. Bentur, David Sidransky, Jonathan Brammer, Barbara Pro, Christopher Fox, Steven Horwitz

Blood (2025) 146 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2025-3634

Published: 2025

Journal Articles

Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia

Enrica Marchi, Tapan Kadia, Ryotaro Nakamura, Christina Poh, Costas Yannakou, Mitul Gandhi, Jasmine Zain, Steven Horwitz, Jenna Reed, Jennifer Richardson, Ruoshi Shi, Kimberley Dilley, Wan-Jen Hong, Nenad Tomasevic, Natali Pflug, Thierry Lamy, Marco Herling, Jonathan Brammer, Thomas Loughran

Blood (2025) 146 (Supplement 1): 777.

https://doi.org/10.1182/blood-2025-777

Published: 2025

Journal Articles

Acute Pulmonary Toxicity By Mycophenolate Mofetil (MMF) after Haploidentical Stem Cell Transplant (SCT)

Rohtesh S. Mehta, MD MPH, MS, Jonathan Brammer, MD, Elizabeth J Shpall, MD, Richard E. Champlin

Blood (2014) 124 (21): 5860.

https://doi.org/10.1182/blood.V124.21.5860.5860

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Targeting the methylome in T-LGL leukemia: Pre-clinical analysis and Results of a Phase I trial with oral 5-azacytidine

PRMT5 is a therapeutic vulnerability in cutaneous T-cell lymphoma

Allogeneic stem cell transplant results in t-cell prolymphocytic leukemia (T-PLL): A collaborative multi-center study cohort

Functional analysis of STAT3 activating mutations in LGL leukemia reveals epigenetic reprograming and therapeutic vulnerabilities.

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

A multicenter real-world analysis (RWA) of primary cutaneous anaplastic large cell lymphoma (PCALCL) treated in the era of targeted therapies

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial - impact of prior therapy and expanded safety analysis

Initial clinical data from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with large granular lymphocytic leukemia

Acute Pulmonary Toxicity By Mycophenolate Mofetil (MMF) after Haploidentical Stem Cell Transplant (SCT)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only